Ingredients That Differentiate Joint Care Products Should Thrive as Glucosamine Flattens
May 1, 2005 12:00 PM
Despite survey data showing that safety concerns prompted many arthritis sufferers to switch from drugs to supplements last fall, some manufacturers of joint-care supplements said the COX-2 inhibitor recalls and warnings were insignificant to the category. “We’re seeing an increase in sales, but I don’t believe it has anything to do with the prescription drug issue,” said Harvey Kamil, president & chief financial officer of NBTY, which markets Osteo Bi-Flex and other joint care products. “It just has to do with the fact that these products work. People get relief.”
Other executives said the impacts are ambiguous. “It’s very difficult to pinpoint the positive or negative impact of that kind of news,” said Terry Keller, vice president of sales for Weider Nutrition International, which markets Lubriflex, Move Free and other joint care products under its Schiff label. “The joint care category, both brand and private label, is so heavily promoted that it’s hard to isolate any particular uptick that could be attributed to those negative COX-2 incident reports.”
Sign in to
view the full article
Why Join?
- In-depth perspective on the $226 billion global nutrition industry
- Access to weekly news updates
- Downloadable data files, presentations, and more
NBJ Spotlight
Direct Selling in the Nutrition Industry VIII
In this 32-page issue, NBJ reviews the sales performance, outlook and emerging trends for the direct-sales channels within the U.S. nutrition industry...
Of Interest
NBJ Events Calendar
Check out all the newest events happening in your area!
View the events calendar here.
Market Research Reports Center
2009 Kid’s nutrition report
This report is a must have for any company operating in, attempting to move into or simply evaluating this category with timely and actionable information and insights.
